Botanix Pharmaceuticals company info

What does Botanix Pharmaceuticals do?
Botanix Pharmaceuticals (ASX:BOT) is a dermatology company focused on the development and commercialization of innovative and effective topical treatments for a range of serious skin conditions. The company has a portfolio of products in clinical development, including its lead product, Sofpironium Bromide, which is currently in Phase 3 clinical trials for the treatment of primary axillary hyperhidrosis (excessive underarm sweating). Botanix is also developing other products for the treatment of atopic dermatitis, rosacea, and acne. The company's products are based on a proprietary technology platform called Australasian Botanical Products (ABP), which harnesses the power of natural plant extracts to develop new and effective treatments for skin conditions.
Botanix Pharmaceuticals company media
Company Snapshot

Is Botanix Pharmaceuticals a public or private company?

key
Ownership
Public

How many people does Botanix Pharmaceuticals employ?

people
Employees
15

What sector is Botanix Pharmaceuticals in?

pie chart
Sector
Health Care

Where is the head office for Botanix Pharmaceuticals?

location pin
Head Office
Pennsylvania, United States

What year was Botanix Pharmaceuticals founded?

founded flag
Year Founded
1984
What does Botanix Pharmaceuticals specialise in?
/Biotech /Medtech /Pharmaceutical /Dermatology /Treatment /Healthcare /Health

What are the products and/or services of Botanix Pharmaceuticals?

Overview of Botanix Pharmaceuticals offerings
Sofpironium Bromide for Primary Axillary Hyperhidrosis: Botanix is developing Sofpironium Bromide, a novel topical treatment for primary axillary hyperhidrosis (excessive underarm sweating). The company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Sofpironium Bromide, and a decision is expected in Q3 2023.
BTX-1503 for Moderate to Severe Acne: Botanix is developing BTX-1503, a novel topical treatment for moderate to severe acne. The company has completed a Phase 2 clinical trial of BTX-1503, and the results were positive. Botanix is planning to initiate a Phase 3 clinical trial of BTX-1503 in 2023.
BTX-1702 for Rosacea: Botanix is developing BTX-1702, a novel topical treatment for rosacea. The company has completed a Phase 1b/2 clinical trial of BTX-1702, and the results were positive. Botanix is planning to initiate a Phase 3 clinical trial of BTX-1702 in 2023.
BTX-1204A for Atopic Dermatitis: Botanix is developing BTX-1204A, a novel topical treatment for atopic dermatitis. The company has completed a canine proof-of-concept study for BTX-1204A, and the results were positive. Botanix is planning to initiate a Phase 1 clinical trial of BTX-1204A in 2023.
BTX-1801 for Antimicrobial Applications: Botanix is developing BTX-1801, a novel topical antimicrobial agent. The company has completed a Phase 2a clinical trial of BTX-1801, and the results were positive. Botanix is planning to initiate a Phase 2b clinical trial of BTX-1801 in 2023.

Who is in the executive team of Botanix Pharmaceuticals?

Botanix Pharmaceuticals leadership team
  • Mr. Vincent P. Ippolito
    Mr. Vincent P. Ippolito
    MD & Executive Chairman
  • Dr. Howie  McKibbon
    Dr. Howie McKibbon
    Chief Executive Officer
  • Mr. Matthew  Callahan L.L.B., M.B.A., MBA LLB
    Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB
    Executive Director
  • Dr. Jack  Hoblitzell Ph.D.
    Dr. Jack Hoblitzell Ph.D.
    Senior Vice President of Pharmaceutical Development
  • Dr. Patricia S. Walker M.D., Ph.D.
    Dr. Patricia S. Walker M.D., Ph.D.
    Chief Medical Adviser
  • Ms. Susan Patricia Park A.C.A., A.C.I.S., ACSA, AGIA, B.Com., F Fin, FCIS
    Ms. Susan Patricia Park A.C.A., A.C.I.S., ACSA, AGIA, B.Com., F Fin, FCIS
    Company Secretary